Primary |
Diffuse Large B-cell Lymphoma |
18.1% |
Prophylaxis |
10.9% |
Hodgkin's Disease |
9.5% |
Breast Cancer |
8.1% |
Non-hodgkin's Lymphoma |
7.0% |
Multiple Myeloma |
6.6% |
Ovarian Cancer Recurrent |
5.8% |
Product Used For Unknown Indication |
4.9% |
Acute Lymphocytic Leukaemia |
4.3% |
Burkitt's Lymphoma |
4.0% |
B-cell Lymphoma |
3.7% |
Lymphoma |
3.2% |
Ovarian Cancer |
2.8% |
Mantle Cell Lymphoma |
2.0% |
Breast Cancer Metastatic |
1.7% |
Constipation |
1.7% |
Chronic Lymphocytic Leukaemia |
1.5% |
Sarcoma |
1.5% |
Bone Sarcoma |
1.4% |
Stomatitis |
1.3% |
|
Interstitial Lung Disease |
8.6% |
Pneumocystis Jiroveci Pneumonia |
7.4% |
Off Label Use |
7.3% |
Death |
6.7% |
Vomiting |
6.7% |
White Blood Cell Count Decreased |
6.7% |
Neutropenia |
5.8% |
Pyrexia |
5.4% |
Sepsis |
5.3% |
Ovarian Cancer |
4.9% |
Pneumonia |
4.7% |
Febrile Neutropenia |
4.4% |
Palmar-plantar Erythrodysaesthesia Syndrome |
4.3% |
Stomatitis |
3.8% |
Pulmonary Toxicity |
3.6% |
Renal Failure |
3.1% |
Hepatitis B |
3.0% |
Thrombocytopenia |
2.9% |
Myocardial Infarction |
2.7% |
Infection |
2.6% |
|
Secondary |
Diffuse Large B-cell Lymphoma |
26.1% |
Drug Use For Unknown Indication |
11.4% |
Breast Cancer |
7.8% |
Prophylaxis |
7.0% |
Product Used For Unknown Indication |
6.3% |
Non-hodgkin's Lymphoma |
5.9% |
B-cell Lymphoma |
5.5% |
Hodgkin's Disease |
4.8% |
Multiple Myeloma |
4.3% |
Mantle Cell Lymphoma |
3.1% |
Ovarian Cancer Recurrent |
2.9% |
Burkitt's Lymphoma |
2.9% |
Acute Lymphocytic Leukaemia |
2.5% |
Lymphoma |
2.4% |
T-cell Lymphoma |
1.7% |
Constipation |
1.3% |
Peripheral T-cell Lymphoma Unspecified |
1.3% |
Stomatitis |
1.1% |
Sarcoma |
0.9% |
Hypertension |
0.9% |
|
Febrile Neutropenia |
16.4% |
Neutropenia |
8.3% |
White Blood Cell Count Decreased |
7.0% |
Pyrexia |
6.8% |
Vomiting |
6.2% |
Sepsis |
5.6% |
Death |
4.4% |
Thrombocytopenia |
4.1% |
Pneumonia |
4.1% |
Off Label Use |
4.0% |
Interstitial Lung Disease |
3.8% |
Pneumocystis Jiroveci Pneumonia |
3.8% |
Pulmonary Embolism |
3.7% |
Palmar-plantar Erythrodysaesthesia Syndrome |
3.7% |
Septic Shock |
3.6% |
Infection |
3.3% |
Stomatitis |
3.2% |
Myelodysplastic Syndrome |
2.8% |
Ovarian Cancer Recurrent |
2.7% |
Acute Myeloid Leukaemia |
2.3% |
|
Concomitant |
Drug Use For Unknown Indication |
17.6% |
Diffuse Large B-cell Lymphoma |
13.4% |
Breast Cancer |
8.9% |
Non-hodgkin's Lymphoma |
8.7% |
B-cell Lymphoma |
8.3% |
Product Used For Unknown Indication |
6.2% |
Lymphoma |
5.4% |
Chemotherapy |
5.0% |
Multiple Myeloma |
4.7% |
Prophylaxis |
4.1% |
Acute Lymphocytic Leukaemia |
3.2% |
Hiv Infection |
2.5% |
Hodgkin's Disease |
2.3% |
Mantle Cell Lymphoma |
1.8% |
Chronic Lymphocytic Leukaemia |
1.7% |
T-cell Lymphoma |
1.5% |
Burkitt's Lymphoma |
1.4% |
Breast Cancer Metastatic |
1.1% |
Pain |
1.1% |
Hypertension |
1.0% |
|
Febrile Neutropenia |
12.0% |
Progressive Multifocal Leukoencephalopathy |
9.6% |
Neutropenia |
7.3% |
Vomiting |
6.8% |
Pneumocystis Jiroveci Pneumonia |
6.1% |
Thrombocytopenia |
5.7% |
Pyrexia |
5.1% |
Sepsis |
5.1% |
Respiratory Failure |
4.7% |
Death |
4.6% |
White Blood Cell Count Decreased |
4.4% |
Septic Shock |
4.0% |
Renal Failure Acute |
3.6% |
Weight Decreased |
3.5% |
Renal Failure |
3.3% |
Hepatitis B |
3.2% |
Interstitial Lung Disease |
2.8% |
Pancytopenia |
2.8% |
White Blood Cell Count Increased |
2.8% |
Drug Ineffective |
2.6% |
|
Interacting |
Non-hodgkin's Lymphoma |
22.0% |
Non-hodgkin's Lymphoma Unspecified Histology Aggressive |
14.6% |
Product Used For Unknown Indication |
9.8% |
Drug Use For Unknown Indication |
8.1% |
Diffuse Large B-cell Lymphoma |
6.5% |
Hodgkin's Disease |
6.5% |
Bone Sarcoma |
4.9% |
Breast Cancer |
4.1% |
Lymphoma |
4.1% |
Breast Cancer Metastatic |
3.3% |
Prophylaxis Of Nausea And Vomiting |
3.3% |
Delirium |
2.4% |
Bone Pain |
1.6% |
Histoplasmosis |
1.6% |
Hormone Therapy |
1.6% |
Neoplasm Malignant |
1.6% |
Prophylaxis |
1.6% |
Acne |
0.8% |
Acute Lymphocytic Leukaemia |
0.8% |
Arthralgia |
0.8% |
|
Vomiting |
30.0% |
Agranulocytosis |
10.0% |
Pyrexia |
10.0% |
Relapsing Fever |
10.0% |
Drug Interaction |
5.0% |
Fat Embolism |
5.0% |
Leukopenia |
5.0% |
Nausea |
5.0% |
Neoplasm Progression |
5.0% |
Neutropenia |
5.0% |
Tachycardia |
5.0% |
Tumour Lysis Syndrome |
5.0% |
|